Zobrazeno 1 - 10
of 100
pro vyhledávání: '"K. B. MIRZAEV"'
Autor:
A. S. Zhiryakova, N. P. Denisenko, A. V. Kryukov, K. A. Akmalova, S. N. Tuchkova, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 178-189 (2024)
INTRODUCTION. The variability in patient response to non-steroidal anti-inflammatory drugs (NSAIDs) may be due to genetic polymorphisms. Decreased-function or non-functional CYP2C9 alleles are known to be significant contributors to response variabil
Externí odkaz:
https://doaj.org/article/ce69b2b2c49b44658781ec122244b276
Autor:
D. A. Sychev, K. B. Mirzaev, M. S. Cherniaeva, N. V. Shakhgildyan, Sh. P. Abdullaev, N. P. Denisenko, Zh. A. Sozaeva, A. A. Kachanova, V. R. Shastina, S. V. Gorbatenkova
Publikováno v:
Acta Biomedica Scientifica, Vol 8, Iss 6, Pp 51-80 (2024)
Background. The use of P-glycoprotein (P-gp) inhibitors and carriage of certain ABCB1 polymorphisms can lead to increased concentrations of rivaroxaban and the development of bleeding.The aim of the study. To study the features of drug-drug interacti
Externí odkaz:
https://doaj.org/article/80ceb717f6c74d60a892134e49db667e
Autor:
Sh. P. Abdullaev, N. P. Denisenko, I. I. Temirbulatov, A. A. Kachanova, S. N. Tuchkova, E. V. Mikhaylenko, A. V. Kryukov, T. T. Valiev, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Acta Biomedica Scientifica, Vol 8, Iss 6, Pp 23-30 (2024)
Background. There is a mounting evidence in the scientific literature that susceptibility to SARS-CoV-2 infection could vary. The severity of COVID-19 symptoms can range from asymptomatic to severe respiratory failure, requiring prolonged artificial
Externí odkaz:
https://doaj.org/article/7c25c2af93a1434da4254760586fc038
Autor:
Yu. V. Shevchuk, A. V. Kryukov, I. I. Temirbulatov, I. V. Sychev, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 3, Pp 228-239 (2023)
Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim
Externí odkaz:
https://doaj.org/article/6b3b5a75901b45d09a94422a067614ef
Autor:
N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 19, Iss 5, Pp 470-478 (2023)
Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual equilibrium concentrations (Cmin,ss) of rivaroxaban in p
Externí odkaz:
https://doaj.org/article/9a8bd307ca844343b2cc8835a800342f
Autor:
I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, S. P. Abdullaev, A. V. Petrova, E. P. Tkach, A. V. Shipacheva, D. A. Sychev
Publikováno v:
Антибиотики и Химиотерапия, Vol 68, Iss 5-6, Pp 55-61 (2023)
The aim of the study was to evaluate the associations of different variants of AOX1 and CYP1A2 genes with safety parameters of favipiravir therapy in patients with COVID-19. Material and Methods. The study included 86 patients hospitalized at Moscow
Externí odkaz:
https://doaj.org/article/74a0d8640e3b45ad87934a6e71cebedc
Autor:
I. V. Sychev, N. P. Denisenko, A. A. Kachanova, A. V. Lapshtaeva, Sh. P. Abdullaev, L. N. Goncharova, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 2, Pp 231-240 (2023)
Angiotensin-converting enzyme inhibitors (ACEIs) are among the most prescribed and effective medicinal products for the treatment of several cardiovascular diseases. According to a number of studies, 30% of patients taking ACEIs develop adverse drug
Externí odkaz:
https://doaj.org/article/612fe468ef6f4c729519954a14d7b41a
Autor:
E. V. Balanovskaya, I. O. Gorin, G. Yu. Ponomarev, V. Yu. Pylev, R. O. Belov, E. A. Pocheshkhova, Sh. P. Abdullaev, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 22, Iss 11 (2023)
Significant differences between the gene pools of Russian peoples require the development of ethno- regional adapted pharmacogenetic tests and the identification of priority regions for their implementation.Aim. To develop a genogeographic technology
Externí odkaz:
https://doaj.org/article/a6e0b7bb89ef465b9d1380b99b603ca4
Autor:
A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 4, Pp 326-344 (2022)
The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential
Externí odkaz:
https://doaj.org/article/5d9ff01bf50b46dfb11a1965a596882f
Autor:
I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV
Publikováno v:
Антибиотики и Химиотерапия, Vol 67, Iss 7-8, Pp 45-50 (2022)
The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters of remdesivir therapy in patients with COVID-19.Material and methods. The study included 156
Externí odkaz:
https://doaj.org/article/529d41e696844e8bbf54c26567f38e08